Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials

IMPORTANCE: The subtype of pancreatic ductal adenocarcinoma cancer (PDAC) with DNA damage repair (DDR) deficiency from BRCA1/2 variants has a favorable prognosis and is sensitive to platinum analogues and poly–(adenosine diphosphate–ripose) polymerase (PARP) inhibition with olaparib. Approximately 1...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Javle, Milind, Shacham-Shmueli, Einat, Xiao, Lianchun, Varadhachary, Gauri, Halpern, Naama, Fogelman, David, Boursi, Ben, Uruba, Syeda, Margalit, Ofer, Wolff, Robert A., Golan, Talia
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934074/
https://ncbi.nlm.nih.gov/pubmed/33662100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.0006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados